Home LiteratureArticle Details

PMID: 3802114 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.

Cancer treatment reports ·Vol. 71 ·No. 2 ·1987-02-00 ·Pages 187-9

O'Donnell MR, Forman SJ, Levine AM, Territo M, Farbstein MJ, Fahey JL, Gill P, Lazar G, Nademanee A, Neely S

Abstract

A phase II trial of cytarabine, cisplatin, and etoposide was conducted in 38 patients with refractory stage III and IV non-Hodgkin's lymphoma. There were two complete and nine partial responses (32%) among 35 evaluable patients. Response rate in patients with large cell lymphoma was 45%. The dose-limiting toxic effect was myelosuppression in 66% of patients.

MeSH Terms

Antineoplastic Combined Chemotherapy Protocols/adverse effects,therapeutic use Cisplatin/administration & dosage Cytarabine/administration & dosage Drug Evaluation Etoposide/administration & dosage Female Hematologic Diseases/chemically induced Humans Lymphoma, Non-Hodgkin/drug therapy,pathology Male

Chemicals

Cytarabine Etoposide Cisplatin

Authors & Affiliations

10 authors, click to expand affiliations / ORCID

O'Donnell M R

Forman S J

Levine A M

Territo M

Farbstein M J

Fahey J L

Gill P

Lazar G

Nademanee A

Neely S

Article Info

Journal

Cancer treatment reports

Abbr.

Cancer Treat Rep

ISSN

0361-5960

Published

1987-02-00

Pages

187-9

Language

English

Region

United States

NLM ID

7607107

Subset

Grants

NCI NIH HHS · CA-33572 · United States

External Links

PubMed source

Analysis Services

Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.

Contact

WeChat Official Account